Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$2.42 USD
-0.13 (-5.10%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.42 USD
-0.13 (-5.10%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Up 21.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE's Loss Wider Than Expected in Q4, Pipeline in Focus
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the fourth quarter.
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the second quarter.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -11.54% and 89.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -14.29% and 57.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Down 9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
by Zacks Equity Research
FATE reports a wider Q4 loss on increased R&D expenses.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update
by Kinjel Shah
Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.